Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials

HERO trial terminated early (67 of 90 planned participants randomized); all efficacy data are considered exploratoryHQ-CT scores fell by Week 2 of dose escalation on ARD-101 and returned to near baseline within two